
|Videos|December 14, 2017
Dr. Chari on Challenges in Sequencing Agents for Multiple Myeloma
Author(s)Ajai Chari, MD, PhD
Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses challenges in sequencing agents for patients with multiple myeloma.
Advertisement
Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses challenges in sequencing agents for patients with multiple myeloma.
According to Chari, the use of daratumumab (Darzalex) induction therapy and ixazomib (Ninlaro) in the maintenance setting are making patients refractory to a different drug class.
Many researchers are investigating how quickly chimeric antigen receptor (CAR) T-cell therapy can be given to patients based on the risk value, explains Chari.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5






























































